Affectis Granted Patent for AFC-5128, other P2X7 Antagonists

25 January 2012

Martinsried, Germany, January 25, 2012 – Affectis Pharmaceuticals AG, a pharmaceutical company developing novel drugs for the treatment of neuroinflammatory diseases, announced today that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis.

Attachments:

File	File size
Press Release Affectis_EP patent AFC-5128 20120125.pdf	123 Kb